A platform for rapidly generating antibodies against diverse bacterial targets, applicable to monoclonal antibody development and the expedited evaluation of potential vaccine antigens

A platform for rapidly generating antibodies against diverse bacterial targets, applicable to monoclonal antibody development and the expedited evaluation of potential vaccine antigens
Seamless integration of large nitrogen fixation clusters into virtually any bacterial strain – unlocking exciting new frontiers in biofertilisers
Jialuo is a Commercialisation Junior Officer for the Faculty of Engineering at Imperial College London
Joanna is a Commercialisation Executive working 50% in the Faculty of Natural Science and 50% in the Faculty of Medicine
Ryhan is a Junior Officer for Commercialisation at Imperial’s Faculty of Natural Sciences.
A nanoparticle drug platform that can deliver small molecule drugs over a sustained period in a stable, low-toxic manner.
These novel compounds could be used in the treatment of antibiotic resistant bacterial infections and demonstrate that inhibitors of NorA efflux can prevent the emergence of further resistant strains.
Efficient and localised suppression of wild pest populations
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.